Epizyme Inc (EPZM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Epizyme Inc (EPZM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9837
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. The company discovers and develops small molecule inhibitors of a class of enzymes, namely, histone methyl transferases (HMTs) and other chromatin modifying proteins (CMPs). Using its proprietary platform and collaborations, the company has initiated the identification and development of small molecule inhibitors of CMPs and HMTs. The company is developing product candidates for the treatment of solid tumors, non-hodgins lymphoma, mesothelioma, ovarian cancer, molecularly targeted tumors and sickle cell disease. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc (EPZM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Epizyme Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10
Epizyme Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Epizyme Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Epizyme Enters into Partnership with US Oncology Research 12
Epizyme Enters into Agreement with Genentech 13
Strata Oncology Enters into Agreement with EpiZymev 14
Epizyme Enters into Research Agreement with National Cancer Institute 15
Epizyme Enters into Agreement with Foundation Medicine 16
Epizyme Enters into Agreement with Genentech 17
Epizyme Enters into Agreement with Lymphoma Study Association 18
Licensing Agreements 19
Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 19
Equity Offering 21
Epizyme Raises USD86.2 Million in Public Offering of Shares 21
Epizyme Raises USD161 Million in Public Offering of Shares 23
EpiZyme Raises USD1.9 Million in Public Offering of Shares 25
Epizyme Raises USD138 Million in Public Offering of Shares 26
Epizyme Raises USD139 Million in Public Offering of Shares 28
EpiZyme Announces Exercise Of Underwriters Over Allotment Option Of Public Offering Of Shares For US$107.5 Million 30
EpiZyme Completes IPO For US$89 Million 32
Epizyme Inc – Key Competitors 34
Epizyme Inc – Key Employees 35
Epizyme Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Nov 02, 2018: Epizyme reports third quarter 2018 financial results and Tazemetostat progress 37
Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates 39
May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates 41
Mar 13, 2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 01, 2017: Epizyme Reports Third Quarter 2017 Operating Results and Company Updates 45
Aug 04, 2017: Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress 46
May 08, 2017: Epizyme Reports First Quarter 2017 Results and Provides Corporate Update 48
Mar 09, 2017: Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals 49
Corporate Communications 51
Jul 23, 2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer 51
Mar 12, 2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors 52
Aug 15, 2017: Epizyme Announces Leadership Transition for Finance Organization 53
Mar 09, 2017: Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company 54
Feb 07, 2017: Epizyme Elects Kevin Conroy to its Board of Directors 55
Clinical Trials 56
Dec 11, 2017: Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Epizyme Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Epizyme Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Epizyme Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10
Epizyme Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Epizyme Enters into Partnership with US Oncology Research 12
Epizyme Enters into Agreement with Genentech 13
Strata Oncology Enters into Agreement with EpiZymev 14
Epizyme Enters into Research Agreement with National Cancer Institute 15
Epizyme Enters into Agreement with Foundation Medicine 16
Epizyme Enters into Agreement with Genentech 17
Epizyme Enters into Agreement with Lymphoma Study Association 18
Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 19
Epizyme Raises USD86.2 Million in Public Offering of Shares 21
Epizyme Raises USD161 Million in Public Offering of Shares 23
EpiZyme Raises USD1.9 Million in Public Offering of Shares 25
Epizyme Raises USD138 Million in Public Offering of Shares 26
Epizyme Raises USD139 Million in Public Offering of Shares 28
EpiZyme Announces Exercise Of Underwriters Over Allotment Option Of Public Offering Of Shares For US$107.5 Million 30
EpiZyme Completes IPO For US$89 Million 32
Epizyme Inc, Key Competitors 34
Epizyme Inc, Key Employees 35
Epizyme Inc, Subsidiaries 36

List of Figures
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Epizyme Inc (EPZM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Smartac Group China Holdings Ltd (395):企業の財務・戦略的SWOT分析
    Smartac Group China Holdings Ltd (395) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Mitel Networks Corporation:企業のM&A・事業提携・投資動向
    Mitel Networks Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitel Networks Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Edison SpA:企業の発電所・SWOT分析2018
    Edison SpA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • The Cheesecake Factory Incorporated:企業の戦略・SWOT・財務分析
    The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Invacare Corporation (IVC)-医療機器分野:企業M&A・提携分析
    Summary Invacare Corporation (Invacare) is a medical equipment company which develops, manufactures and distributes healthcare products for non-acute care, such as the home healthcare and long term care markets. The major products include power wheelchairs, custom manual wheelchairs, personal mobili …
  • Enterprise Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Enterprise Therapeutics Ltd (Enterprise Therapeutics) is a drug discovery company that offers research and development of novel therapies for the treatment of respiratory diseases. The company also identifies novel targets and compounds which reduces the mucus production. It provides therape …
  • Techpool Bio-Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Techpool Bio-Pharma Co Ltd (Techpool Bio-Pharma) is a biopharmaceutical company. The company manufactures urinary protein biopharmaceuticals in critical care conditions. The company’s products include ulinastatin for injection, urinary kallidinogenase for injection, urokinase for injection a …
  • Ecology and Environment Inc (EEI):企業の財務・戦略的SWOT分析
    Summary Ecology and Environment Inc (E&E) is an environmental consultancy service provider. The company provides air quality, cultural resources, emergency planning: mitigation and prevention, preparedness, and response and recovery, and water resources planning; climate and sustainable development; …
  • John Keells Holdings PLC (JKH.N0000):企業の財務・戦略的SWOT分析
    Summary John Keells Holdings PLC (John Keells) is a business and consumer services company that provides hotel management services. The company offers services such as airline and aviation services, cinnamon hotels and resorts services, holiday and tour consulting services, port and marine fuel serv …
  • Passenger Rail Agency of South Africa:企業の戦略的SWOT分析
    Passenger Rail Agency of South Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Stratasys Ltd:企業の戦略・SWOT・財務情報
    Stratasys Ltd - Strategy, SWOT and Corporate Finance Report Summary Stratasys Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • NuVasive Inc (NUVA):企業の財務・戦略的SWOT分析
    NuVasive Inc (NUVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Taiga Biotechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Taiga Biotechnologies Inc (Taiga Biotech) is a biopharmaceutical company that develops protein and cellular therapies. The company develops therapies for diseases including cancers and infectious diseases. It provides pipeline products such as programs such as stem cell therapy and target sp …
  • Urstadt Biddle Properties Inc:企業の戦略・SWOT・財務分析
    Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Bombril SA (BOBR4):企業の財務・戦略的SWOT分析
    Bombril SA (BOBR4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Fives:企業の戦略・SWOT・財務情報
    Fives - Strategy, SWOT and Corporate Finance Report Summary Fives - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Marmen Inc:企業の戦略的SWOT分析
    Marmen Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Gildan Activewear Inc (GIL):企業の財務・戦略的SWOT分析
    Gildan Activewear Inc (GIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Global Bio-chem Technology Group Company Limited (809):企業の財務・戦略的SWOT分析
    Global Bio-chem Technology Group Company Limited (809) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆